<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001845</url>
  </required_header>
  <id_info>
    <org_study_id>53001</org_study_id>
    <nct_id>NCT01001845</nct_id>
  </id_info>
  <brief_title>Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients</brief_title>
  <official_title>Comparative Effects of Milk Thistle Extract With Vitamin-E on Oxidative Stress Biomarkers in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For end-stage renal disease (ESRD) patients, cardiovascular disease remains the single most
      common cause of excess morbidity and mortality. Among the examined nontraditional risk
      factors, an increase in oxidative stress as well as inflammation are postulated to contribute
      to excessive cardiovascular risk in this population.

      Flavonoids are naturally occurring substances that possess various pharmacological actions
      and therapeutic applications. Some due to their phenolic structures have antioxidant effect
      and inhibit free radical-mediated processes, as well as anti-inflammatory effects.
      Silymarin,a mixture of three isomeric flavonolignans, is isolated from milk thistle (Silybum
      marianum) seeds, and is proven to have anti-oxidant, anti-inflammatory, cell regenerating,
      and antifibrotic action.

      In this study, the effect of silymarin on oxidative stress and inflammation (2 major risk
      factors for cardiovascular morbidity and mortality in hemodialysis patients)is evaluated, and
      compared to vit E, a well known antioxidant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC Glutathion Peroxidase level</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma malondialdehyde</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hemodialysis</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Lifestyle counseling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vit E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg 2 times per day for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk Thistle extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vit E + Milk Thistle Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Thistle extract</intervention_name>
    <description>1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks</description>
    <arm_group_label>Milk Thistle extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vit E</intervention_name>
    <description>200 mg twice daily for 3 weeks</description>
    <arm_group_label>vit E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vit E + Milk Thistle extract</intervention_name>
    <description>200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks</description>
    <arm_group_label>vit E + Milk Thistle Extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All hemodialysis patients age 18-60

          -  On hemodialysis for over 3 months, 3 times a week, and for 4 hours each time

          -  Signed informed consent

        Exclusion Criteria:

          -  Heart Failure NYHA Class III or IV

          -  Recent MI (within 1 year)

          -  Use of anti-oxidant supplements: N-acetyl-cystein, Omega 3, Vit C, Vit E, green tea,
             soy extracts, pomegranate extract, grape extract..

          -  Hepatitis B or C

          -  Active Infection

          -  Psychiatric illness

          -  Active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghazal Vessal, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bahram Shahriari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology Urology Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>masoumeh Akmali, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemazi Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>71345</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jamshid Roozbeh</name_title>
    <organization>Nephrology and Urology Research Center</organization>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>plasma malondialdehyde</keyword>
  <keyword>Glutathion peroxidase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

